|$65.000||CAUTIOUS||NORTH AMERICAN - LARGE||Yes|
Splitting as of Jan 2nd. Trading ‘as is’ in December. ‘New Abbot’ is their nutritional, diagnostics, vascular and diversified business, very solid sales outlooks. Thinks there is more upside in the Drug exploration part. Humera is one of the 5 biggest drugs globally. 5 drugs in clinical trials. A really good pipeline.
Vice President of Investments, Stone Funds